{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-080484","form_type":"8-K","ticker":"OSTX","cik":"0001795091","company_name":"OS Therapies Inc","filed_at":"2025-08-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.016517+00:00","generated_at":"2026-05-17T09:58:48.909257+00:00","sec_items":["1.02","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"OS Therapies terminates $15M equity line; $4.2M raised, burn reduced","bullets":["Terminated ELOC Purchase Agreement with Square Gate effective Aug 26, 2025; no outstanding borrowings or fees.","Recent warrant exercise exchange provided $4.2M gross proceeds to fund operations into mid-2026.","Projected monthly burn in H2 2025 significantly lower than H1 2025, completing Phase 2b and Phase 1b treatment phases.","Company focusing capital on advancing OST-HER2 toward approval and analyzing OST-504 prostate cancer data."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-080484","json":"https://secwatch.observer/filing/0001213900-25-080484.json","markdown":"https://secwatch.observer/filing/0001213900-25-080484.md","text":"https://secwatch.observer/filing/0001213900-25-080484.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1795091/000121390025080484/0001213900-25-080484-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1795091/000121390025080484/ea0254579-8k_ostherap.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T09:58:48.909257+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}